A significant accomplishment for the Valneva chikungunya vaccine as FDA considers its application

A single-dose, live-attenuated vaccine candidate called VLA1553 is being developed to combat the extremely risky chikungunya virus. The US Food and Drug Administration (FDA) is now assessing Valneva‘s biologics licensing application for its single-shot chikungunya vaccine candidate, according to the business that specializes in global vaccinations.

In fact, it has been determined that the VLA1553-related application is sufficiently finished to allow for a substantial evaluation, with the review categorization being set as “priority.” The FDA now aims to act on the application by the review goal date for the candidate, which has been set as August of this year. However, the agency’s confirmation of filing does not imply that a license will be granted, nor does it constitute any assessment of the suitability of the information provided.

A single-dose, live-attenuated vaccine candidate called VLA1553 is being developed to combat the extremely lethal chikungunya virus, which has now been reported in more than 100 nations. By eliminating a portion of the chikungunya virus genome, the treatment was developed. In order to make VLA1553 more affordable for low- and middle-income nations, Valneva and the Brazilian institute Instituto Butantan inked a contract in 2021 for the creation, production, and distribution of the vaccine.

Chikungunya is a viral illness spread by mosquitoes that is brought on by the Togaviridae virus. One-third to three-quarters of the population in places where the virus is prevalent are affected by the virus’ frequent large, abrupt outbreaks with high attack rates. Chikungunya is regarded as a serious public health threat because there are currently no preventative vaccinations or efficient therapies. More than three million cases had been reported in the Americas as of July 2022.

As the main mosquito vectors continue to expand throughout the world, the medical and financial burden is anticipated to increase. Up to 97% of humans develop symptoms of sickness three to seven days after the initial mosquito bite as a result of infection.

About chikungunya virus

Chikungunya virus (CHIKV) is a viral disease that is transmitted to humans by infected mosquitoes, primarily the Aedes aegypti and Aedes albopictus species. The virus is most commonly found in Africa, Asia, and the Indian subcontinent, although outbreaks have occurred in other parts of the world, including Europe and the Americas.

The symptoms typically include fever, joint pain, muscle pain, headache, fatigue, and rash. The disease is usually not fatal but can be severe and debilitating, with some patients experiencing chronic joint pain and disability that can last for months or even years. The virus was first identified in Tanzania in 1952, and outbreaks have occurred sporadically since then. The virus is closely related to other mosquito-borne viruses such as dengue and Zika, and can be difficult to distinguish from these diseases based on symptoms alone.

There is currently no specific treatment or vaccine for Chikungunya, and the only way to prevent the disease is by avoiding mosquito bites. Treatment is typically supportive and focused on relieving the symptoms of the disease, such as pain and fever. However, research into potential treatments and vaccines is ongoing, and several candidate vaccines are currently in development, including a live attenuated vaccine being developed by Valneva SE.

Efforts to control this viral infection typically focus on reducing mosquito populations and limiting exposure to mosquitoes, such as through the use of insecticides and mosquito nets. Travelers to areas where Chikungunya is endemic are advised to take precautions such as wearing long sleeves and pants and using insect repellent.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details visit the link- https://irrespub.com/


Leave a Reply

Your email address will not be published. Required fields are marked *


Enjoy this blog? Please spread the word :)

Follow by Email